Tag Archives: ARQL

Analysts’ View: Esperion Therapeutics (ESPR), ArQule (ARQL), SITO Mobile (SITO)

Brokerage Firm Needham upgraded Esperion Therapeutics Inc. (NASDAQ:ESPR) shares from Buy to Strong Buy rating while increasing their price target from $72 to $81.

Esperion Therapeutics, Inc. is a clinical stage biopharmaceutical company.


Investment Analysts at Needham upgraded ArQule Inc. (NASDAQ:ARQL) shares from Hold to Buy rating with a price target of $5.

ArQule, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of pharmaceutical products.


SITO Mobile Ltd. (NASDAQ:SITO) shares were upgraded by analysts at Ladenburg Thalmann from Neutral to Buy rating.

SITO Mobile Ltd. engages in the provision of advertising solutions to businesses, advertisers, and brands.


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE.Info is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://www.crwe.info/disclaimer/